Technical Data
I7662-14P
Interferon beta 1 (beta 1a), Recombinant, Human (IFNb1, IFNb1a)
2ug
|
Technical Data |
|
I7662-14P |
Interferon beta 1 (beta 1a), Recombinant, Human (IFNb1, IFNb1a) |
2ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 166aa of human Interferon-beta 1a expressed in CHO (Chinese Hamster Ovarian) cells is a single, glycosylated polypeptide chain. Molecular Weight: ~22.5kD Biological Activity: The specific activity as determined in a viral resistance assay (human "Wish" cell line and VSV virus or the monkey VERO cell line with EMCV virus) was found to be 270x10^6 IU/mg. Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm. 2. Analysis by RP-HPLC, using a standard solution of IFN-beta as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~22.5kD |
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: ~1mg/ml Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol 2005 Nov;62(11):1681-3. 2. Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. Can J Neurol Sci 2005 Aug;32(3):366-8. 3. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis. BioDrugs 2005;19(5):323-5. 4. Interferon beta-1a overdose in a multiple sclerosis patient. Ann Pharmacother 2005 Nov;39(11):1950-2. 5. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005 Oct;11(5):585-91. 6. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 2005 Dec 15;239(1):67-74.
|
||